Table 3 Stratified analysis of patient background and various interventions (population with renal function displacement)

Case

Sample (n)

63

63

Age (years)

54.4

±

9.0

54.5

±

7.9

0.93

Sex: male (%)

71.4

77.8

0.41

Observation period (years)

5.1

±

2.0

4.6

±

1.8

0.16

Baseline estimated GFR (mL/min/1.73 m²)

42.1

±

46.6

31.5

±

41.4

0.22

Disease

Diabetic nephropathy (%)

27.0

20.6

0.40

Glomerular nephritis (%)

22.2

12.7

0.16

Nephrosclerosis (%)

1.6

6.3

0.37

Hypertension (%)

98.4

100.0

1.00

Diabetes (%)

60.3

61.9

0.86

Contrast agent

Number of contrast agent exposures (time/year)

1.9

±

1.7

―

Amount of contrast agent (mL/year)

40.1

±

54.2

―

Amount of rehydration (mL/year)

3983.4

±

5635.8

969.1

±

1264.9

< 0.01

Main medicine

Hyperkalaemia drug (%)

42.9

49.2

0.48

Phosphate binder (%)

30.2

39.7

0.26

Erythropoiesis-stimulating agent (%)

63.5

69.8

0.45

Spherical carbon adsorbent (AST-120) (%)

27.0

36.5

0.25

Antihypertensive (%)

88.9

95.2

0.19

Diuretic (%)

69.8

58.7

0.19

Diabetes drug (%)

58.7

55.6

0.72

Non-steroidal anti-inflammatory drug (%)

57.1

58.7

0.86

Antibacterial drug (%): Aminoglycosides, Glycopeptides, Others

15.9

11.1

0.43

Anticancer drug (%)

1.6

1.6

1.00

Main surgery

Revascularisation (%)

12.1

0.0

< 0.01

Cardiovascular implantable electronic device, others (%)

6.9

0.9

< 0.01

Heart valve replacement, valvuloplasty (%)

2.2

0.0

0.06

Main prevention

Lifestyle disease prevention (education, guidance) (%)

6.3

3.2

0.68